12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Siltuximab: Phase II data

The double-blind, international, pivotal Phase II MCD2001 trial in 79 patients with MCD who are HIV-negative and human herpes virus 8 (HHV-8)-negative showed that 11 mg/kg IV siltuximab every 3 weeks plus best supportive care (BSC) led to a greater durable tumor and symptomatic response rate, the primary endpoint, vs. placebo plus BSC (34% vs. 0%, p=0.0012). The primary analysis occurred after the last treated patient completed assessments at week 48. Median time to treatment failure was not reached in the siltuximab...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >